Laboratorios Farmaceuticos RoviXMAD:ROVI +0.51%98 Dividend Yield % is 1.57% as of Jun. 25, 2026, which is 43% above its 10-year median of 1.10. GuruFocus rates XMAD:ROVI with a GF Score™ of 98/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 57.95% on this metric.
During the past 12 months, Laboratorios Farmaceuticos Rovi's average Dividends Per Share Growth Rate was -15.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -0.70% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 40.40% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 29.50% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 128.60% per year. The lowest was -16.80% per year. And the median was 4.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ROVI vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Laboratorios Farmaceuticos Rovi Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 0.935100
2025-07-14
2025-07-15
2025-07-16
Cash Dividend
annually
EUR:EUR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Dividend Yield % of 1.57% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 43% above median its historical median of 1.10. Over the past decade, Laboratorios Farmaceuticos Rovi's Dividend Yield % has ranged from 0.30 to 3.28. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #299 out of 516 companies in the Drug Manufacturers industry, placing it in the top 57.9%.
Is Laboratorios Farmaceuticos Rovi's Dividend Yield % too high?
Laboratorios Farmaceuticos Rovi's current Dividend Yield % of 1.57% is 43% above median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 3.28. The Drug Manufacturers industry median Dividend Yield % is 2.01. Laboratorios Farmaceuticos Rovi's value of 1.57% is 21.7% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #299 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 98/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #299 out of 516 companies for Dividend Yield %. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Dividend Yield % is 2.01. Laboratorios Farmaceuticos Rovi's value of 1.57% is 21.7% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Dividend Yield % has ranged from 0.30 to 3.28 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 2.01, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Dividend Yield % of 1.57% is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Dividend Yield % is 1.57%, which is 43% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €59.40 — trading 16.6% above its estimated fair value. The current Dividend Yield % is 1.57%, which is 43% above median its 10-year median of 1.10 and 21.7% below the Drug Manufacturers industry median of 2.01. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Dividend Yield % is 1.57% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €59.40 is trading 16.6% above its estimated GF Value™ of €50.93.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Dividend Yield %: 1.57% (43% above median its 10-year median of 1.10)
GF Value™: €50.93 vs. price of €59.40 (16.6% above fair value)
Industry Position: 21.7% below the Drug Manufacturers median (#299 of 516)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
98GF Score
Get the complete analysis for XMAD:ROVI
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
